Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 2433334 dose-finding study after acute non-cardioembolic ischemic stroke
NL-OMON55288Phase 2Active, not recruiting
- Sponsor
- Bayer
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of asundexian in ischemic stroke (4 arms), sponsored by Bayer. Primary endpoints: Composite of symptomatic ischemic stroke and covert brain infarcts detected by MRI and Composite of ISTH major bleeding and clinically relevant non-major bleeding. Started Oct 2020; status: active, not recruiting.
02
Drugs
asundexian
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NL-OMON55288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55288.